Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Conditions
Brief summary
This randomized, multicenter,open-label, phase II study is to evaluate the effects of PD-1 inhibitor combination with autologous cytokine-induced killer cell immunotherapy in the second-line treatment of patients with metastatic clear cell renal cell carcinoma.
Detailed description
In the experimental group, patients received Camrelizumab injection (SHR-1210) 200mg d1, CIK cells 1x10\^10 d14; Q3W, for 4 cycles; then Camrelizumab injection maintenance treatment for 2 years. In the control group, patients received Camrelizumab injection 200mg d1, Q3W, for 2 years.
Interventions
BIOLOGICALSHR-1210
SHR-1210 injection
BIOLOGICALCIK cells
CIK cells injection
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Subjects who must meet all the following criteria should be selected: 1. Agreeing to participate in this study and signing a written informed consent. 2. Male or female,from 18 to 75 years (including 18 and 75 years). 3. The life expectancy will be longer than 3 months and can be followed up. 4. Patients with metastatic clear cell renal cell carcinoma were confirmed by histological /cytological and imaging examinations. According to RECIST 1.1 standard, there will be at least one measurable lesion. 5. Patients with disease progression after treatment with interferon or TKI. 6. ECOG score will be 0 or 1 within 7 days before randomization. 7. Within 14 days before the start of treatment, the results of laboratory test of blood routine, liver, kidney function and hormone levels must be met the following criteria: White blood cells: more than 3.0 × 109/L; Platelets: more than 100 × 109/L; Neutrophils: more than 1.5 × 109/L; Hemoglobin: more than 80g/L; Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN); Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN; Serum bilirubin: less than 1.25 × ULN; Serum creatinine: less than 1.25 × ULN. Cortisol and thyroid function will be in the normal range. 8. The toxicity and side effects of previous chemotherapy will must be alleviated to grade 1 or below (except hair loss). 9. Female subjects must take effective contraceptive measures throughout the study period; serum or urine pregnancy test results must be negative during screening and the whole study period. 10. Male subjects should take effective contraceptive measures from the beginning of treatment to within 6 months after the end of treatment.
Exclusion criteria
Subjects who meet any of the following criteria could not participate in this study: 1. Other malignant tumors needed treatment within five years. 2. Allogeneic tissue/organ transplantation. 3. Participating in research drug therapy within 4 weeks before the first administration of the trial. 4. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy (except glucocorticoid preconditioned with docetaxel) is being administered within 3 days before the first administration of the experimental therapy. 5. Received anti-tumor monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy or major surgery within 4 weeks before the first use of the drug; received chest radiotherapy greater than 30 Gy within 6 months before the first use of the drug; and received chest radiotherapy with 30 Gy or less within 1 month before the first use of the drug. 6. Previous treatment with PD-1/PD-L1 antibodies. 7. Over the past two years, patients with active autoimmune diseases requiring systemic treatment, such as the use of corticosteroids, or immunosuppressants. Substitution therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary dysfunction) is not a systemic treatment. 8. Patients with congenital or acquired immunodeficiency (e.g. HIV-infected persons), active hepatitis B (HBV-DNA \> 10\^3 copies/ml) or hepatitis C (hepatitis C antibody positive), and HCV-RNA higher than the detection limit of the analytical method. 9. Subjects with active central nervous system (CNS) metastases and/or cancerous meningitis. 10. Patients with active infections requiring systemic intravenous therapy. 11. Mental illness or other illnesses, such as uncontrollable heart disease or pulmonary disease, diabetes, etc. 12. Subjects who are known to be allergic to any of the constituents of the drug being studied. 13. Subjects with a recent history of drug abuse (including alcohol) within one year. 14. Compliance is poor and can not cooperate with clinical research. 15. Female subjects who are pregnant or breastfeeding, or who are expected to be pregnant during the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 3 year | PFS will be calculated from initiation of treatment until first progression, and patients alive in stable state will be censored at the time of last contact. |
Countries
China
Contacts
Primary ContactXiubao Ren, MD. PhD.
Backup ContactLiang Liu, MD. Ph.D
Outcome results
None listed